Verbal Intent and Gaze Cues on Action Prediction in ASD

May 13, 2026 updated by: Shan Gao, University of Electronic Science and Technology of China

Exploration of Verbal Intention and Gaze Clues Characteristics in Children With Autism: Based on Eye Tracking Technology

A 2×2×3 mixed design (intent word × object type × group: TD, ASD, ID) was used. Age-matched children watched videos and judged which object a model would pick; their choices and eye movements were recorded.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Detailed Description

A 2 (intent word: like, dislike) × 2 (object type: mentioned, unmentioned) × 3 (participant group: ASD, TD, ID) mixed experimental design was adopted. Children from the three age-matched groups (29 TD, 22 ASD, 24 ID) completed a video-watching task. In the video, a model was presented with two objects and uttered a sentence containing an intent word, a verb, and a noun, such as "I like to eat oranges." Based on the intent word, trials were divided into "like" and "dislike" conditions. Objects were classified as "mentioned" or "unmentioned" according to the verb and noun used. Participants were required to judge which object the model would pick while watching the video. Their choice responses and eye movements were recorded.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Sichuan
      • Chengdu, Sichuan, China, 611731
        • School of Foreign Languages, University of Electronic Science and Technology of China

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

A total of 80 children (aged 3-10 years) were initially recruited and divided into three groups: 29 typically developing (TD) children (25 boys, 4 girls) from a kindergarten or primary school in Sichuan Province; 26 children with autism spectrum disorder (ASD) (20 boys, 6 girls) from a local disability federation or autism rehabilitation center in Chengdu, Sichuan Province, all clinically diagnosed and assessed with the Autism Diagnostic Observation Schedule (ADOS); and 25 children with intellectual disability (ID) (14 boys, 11 girls) from a disability federation or rehabilitation center in Chengdu, Sichuan Province, all clinically diagnosed. Based on eye-tracking data, 4 ASD participants and 1 ID participant whose total fixation duration accounted for less than 50% of the total trial time were excluded. Consequently, the final sample included 29 TD children (25 boys, 4 girls), 22 ASD children (18 boys, 4 girls), and 24 ID children (13 boys, 11 girls) for data analysis.

Description

Inclusion Criteria:

- Children clinically diagnosed with Autism Spectrum Disorder (ASD). Typically developing (TD) children with no developmental or neurological disorders.

Children clinically diagnosed with Intellectual Disability (ID).

Common criteria for all groups: Normal or corrected-to-normal vision, no color vision deficiencies, normal hearing, and written informed consent provided by their legal guardians.

Exclusion Criteria:

- Failure to meet the study's group-specific screening cutoffs on the Social Responsiveness Scale (SRS) and Social Communication Questionnaire (SCQ).

Failure to meet the study's group-specific screening cutoffs on the Autism Diagnostic Observation Schedule (ADOS).

Known genetic syndromes, significant hearing loss, or uncorrectable visual impairment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Autism Spectrum Disorder (ASD) Group
Typically Developing (TD) Group
Intellectual Disability（ID）Group

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Percentage of Total Fixation Duration on Objects
Time Frame: During the full 13 seconds video presentation
Percentage of Total Fixation Duration on Objects = (Total time fixating on target objects ÷ Total fixation duration across the scene) × 100%. It measures how much of overall viewing time is spent attending to predefined objects, reflecting attentional priority and object-driven cognitive engagement, normalized for individual differences.
During the full 13 seconds video presentation
The time to first fixation on an object within each defined TOI (Time of Interest)
Time Frame: During the 0-2 s, 2-6 s, and 6-8 s intervals of video
Time to First Fixation on an Object within a TOI = time elapsed from TOI onset until the first fixation lands on that object. It measures how quickly attention is drawn to a target, reflecting salience or search efficiency. Shorter times indicate faster capture.
During the 0-2 s, 2-6 s, and 6-8 s intervals of video

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Electronic Science and Technology of China

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 15, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 29, 2026

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 27, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 6, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 13, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 19, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 19, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 13, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • UESTC-GazeLab-04

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Intellectual Disability

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings